Charlotte Eielson Ariyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Charlotte Eielson Ariyan has a total of 670 co-authors. Here are the top co-authors by number of shared publications:
- Travis J. Hollmann
Memorial Sloan Kettering Cancer Center
25 shared publications - Alex D. Corwin
GE Aerospace Research Center, Niskayuna, NY 12309, USA
20 shared publications - Andrea Schietinger
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
20 shared publications - Billel Gasmi
Surgery Branch, National Cancer Institute, Bethesda, MD
20 shared publications - Caitlin J. Jones
Bioinformatics Core, Memorial Sloan Kettering Cancer Center, New York, New York. 4
20 shared publications - Carl Campos
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 1
20 shared publications
Latest Publications
- 25 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
PURPOSE: Although inpatient toxicity associated with tumor-infiltrating lymphocyte (TIL) therapy and interleukin-2 administration is well characterized, risks facing patients after hospital discharge are less understood. Better characterization of outpatient adverse events (AEs) could guide the optimal frequency and duration of follow-up in delivering care for this growing patient population. METHODS: We conducted a retrospective analysis of all patients with advanced melanoma discharged from Memorial Sloan Kettering Cancer Center after receiving investigational or commercial lifileucel from October 2020 to October 2024. We reviewed the incidence and timing of new treatment-related AEs (TRAEs), blood product administration, and readmission among all patients from the time of hospital discharge to the time of the start of a subsequent systemic therapy or death. RESULTS: Over a median follow-up of 5 months from discharge (IQR, 3-18), two patients (3.9%) developed new grade 3 TRAEs, including grade 3 neutropenia and hypoxia occurring 73 and 104 days after discharge, respectively. Four patients (7.8%) were readmitted for TRAEs including cytopenias, dyspnea, and syncope, at a median of 49 days (IQR, 22-81) after discharge. Twelve patients (24%) received outpatient transfusions, including a median of two units of packed RBCs (IQR, 1-4) and four units of platelets (IQR, 2-4). CONCLUSION: Overall, rates of new severe toxicity and treatment-related readmissions were low among patients discharged after lifileucel. These findings support individualized follow-up in this population compared with other cellular therapies and highlight the need for specific postdischarge guidelines for patients receiving TIL therapy.
- 25 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
PURPOSE: Although inpatient toxicity associated with tumor-infiltrating lymphocyte (TIL) therapy and interleukin-2 administration is well characterized, risks facing patients after hospital discharge are less understood. Better characterization of outpatient adverse events (AEs) could guide the optimal frequency and duration of follow-up in delivering care for this growing patient population. METHODS: We conducted a retrospective analysis of all patients with advanced melanoma discharged from Memorial Sloan Kettering Cancer Center after receiving investigational or commercial lifileucel from October 2020 to October 2024. We reviewed the incidence and timing of new treatment-related AEs (TRAEs), blood product administration, and readmission among all patients from the time of hospital discharge to the time of the start of a subsequent systemic therapy or death. RESULTS: Over a median follow-up of 5 months from discharge (IQR, 3-18), two patients (3.9%) developed new grade 3 TRAEs, including grade 3 neutropenia and hypoxia occurring 73 and 104 days after discharge, respectively. Four patients (7.8%) were readmitted for TRAEs including cytopenias, dyspnea, and syncope, at a median of 49 days (IQR, 22-81) after discharge. Twelve patients (24%) received outpatient transfusions, including a median of two units of packed RBCs (IQR, 1-4) and four units of platelets (IQR, 2-4). CONCLUSION: Overall, rates of new severe toxicity and treatment-related readmissions were low among patients discharged after lifileucel. These findings support individualized follow-up in this population compared with other cellular therapies and highlight the need for specific postdischarge guidelines for patients receiving TIL therapy.
- 14 January 2026
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 35 (2) , 237-249
Combining Systemic and Local/Regional Approaches to Improve Immunotherapy Sensitivity
- 14 January 2026
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 35 (2) , 237-249
Combining Systemic and Local/Regional Approaches to Improve Immunotherapy Sensitivity
- Open Access
- 4 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 1907-1909
RP-1 Fires Up Tumors but Fails to Get FDA Approval
- 4 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 1907-1909
Open AccessRP-1 Fires Up Tumors but Fails to Get FDA Approval
- Open Access
- 29 August 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (12) , 1-7
Melanoma Great Debate: Targeted Versus Complete Nodal Dissection Following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold Off on Continued De-Escalation of Surgery?
The management of stage III melanoma has undergone profound change with the advent of effective systemic therapies and the growing use of neoadjuvant immunotherapy. This paper highlights the issues raised and points discussed during the Great Debates session at the 2024 SSO Conference in Atlanta, focusing on the necessity of therapeutic lymph node dissection (TLND) after index lymph node (ILN) surgery.
- 29 August 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (12) , 1-7
Open AccessMelanoma Great Debate: Targeted Versus Complete Nodal Dissection Following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold Off on Continued De-Escalation of Surgery?
The management of stage III melanoma has undergone profound change with the advent of effective systemic therapies and the growing use of neoadjuvant immunotherapy. This paper highlights the issues raised and points discussed during the Great Debates session at the 2024 SSO Conference in Atlanta, focusing on the necessity of therapeutic lymph node dissection (TLND) after index lymph node (ILN) surgery.
- Open Access
- 13 March 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , S591-S598
Surgical Considerations in Tumor-Infiltrating Lymphocyte Therapy: Challenges and Opportunities
- 13 March 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , S591-S598
Open AccessSurgical Considerations in Tumor-Infiltrating Lymphocyte Therapy: Challenges and Opportunities
- Open Access
- 31 October 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (1) , 1-2
Personalized mRNA Vaccines and Contemporary Melanoma Practice
- 31 October 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (1) , 1-2
Open AccessPersonalized mRNA Vaccines and Contemporary Melanoma Practice
- Open Access
- 3 June 2024
- Published by Springer Nature in Research Square
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer
While CD40 agonism is an attractive approach for activating antigen-presenting cells and initiating antitumor responses, previous attempts have encountered limited clinical efficacy coupled with toxicity. We previously demonstrated that interactions between the antibody Fc domain and the inhibitory receptor FcγRIIB are critical for enhanced antitumor activity. Here, we present the results of a phase 1 study on intratumoral administration of an anti-CD40 agonistic antibody (2141-V11) Fc-engineered to enhance FcγRIIB binding. Primary endpoints included safety, maximum tolerated dose (MTD), and recommended phase 2 dose. Secondary objectives included preliminary clinical activity and correlative studies from biospecimens. 2141-V11 was well-tolerated without dose-limiting toxicities and MTD was not reached. In ten evaluable patients with metastatic cancer, the overall response rate was 20%, with complete responses in two patients (melanoma and breast carcinoma) and stable disease in six patients. 2141-V11 induced tumor regression in injected and non-injected lesions, with increased leukocyte infiltration and tertiary lymphoid structures (TLS) formation in post-treatment biopsies. In a humanized mouse model for CD40 and FcγRs, 2141-V11 induced TLS formation in mice bearing orthotopic breast carcinoma, correlating with local and abscopal antitumor effects, systemic immune activation, and immune memory. These findings support the safety and efficacy of 2141-V11, warranting phase 2 studies and suggesting a unique mechanism of action for this Fc-enhanced immunotherapy (NCT04059588).
- 3 June 2024
- Published by Springer Nature in Research Square
Open AccessIntratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer
While CD40 agonism is an attractive approach for activating antigen-presenting cells and initiating antitumor responses, previous attempts have encountered limited clinical efficacy coupled with toxicity. We previously demonstrated that interactions between the antibody Fc domain and the inhibitory receptor FcγRIIB are critical for enhanced antitumor activity. Here, we present the results of a phase 1 study on intratumoral administration of an anti-CD40 agonistic antibody (2141-V11) Fc-engineered to enhance FcγRIIB binding. Primary endpoints included safety, maximum tolerated dose (MTD), and recommended phase 2 dose. Secondary objectives included preliminary clinical activity and correlative studies from biospecimens. 2141-V11 was well-tolerated without dose-limiting toxicities and MTD was not reached. In ten evaluable patients with metastatic cancer, the overall response rate was 20%, with complete responses in two patients (melanoma and breast carcinoma) and stable disease in six patients. 2141-V11 induced tumor regression in injected and non-injected lesions, with increased leukocyte infiltration and tertiary lymphoid structures (TLS) formation in post-treatment biopsies. In a humanized mouse model for CD40 and FcγRs, 2141-V11 induced TLS formation in mice bearing orthotopic breast carcinoma, correlating with local and abscopal antitumor effects, systemic immune activation, and immune memory. These findings support the safety and efficacy of 2141-V11, warranting phase 2 studies and suggesting a unique mechanism of action for this Fc-enhanced immunotherapy (NCT04059588).
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Supplementary Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Supplementary Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma